CyTuVax

Netherlands
Maastricht, Limburg, The Netherlands, 6229

Company profile

CyTuVax company profile

CyTuVax is a young, clinical stage vaccine company, developing solutions to which there is a high medical need. Our interdisciplinary team collaborates with top European research institutions to explore the wide applicability of our technology to develop and enhance the effectiveness of vaccines. Their adjuvant technology induces powerful immune responses, both humoral and cellular, and can be applied in prophylactic and therapeutic vaccine concepts. The powerful adjuvant increases immune responses to higher levels, widely improves the quality of standard vaccines, and decreases the number of vaccine injections. CyTuVax uses its adjuvant technology to develop both: prophylactic vaccines against viral & bacterial pathogens, and therapeutic vaccines against cancer. That is our mission, for which there is a high medical need. The patient is at the core in our vaccine development for which we apply our powerful adjuvant platform technology.

Business identity

Phone number
+31-433881424
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2012-01-01, Year

Headquarters

Postal code
6229
Country code
NL
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
1
Last funding
Grant / 2018-12-01
Investors
1

Categories and groups

Founders and investors

Investors

EISMEA